Liminatus Pharma agrees to merge with InnocsAI in $320 million stock deal

Liminatus Pharma

Liminatus Pharma

LIMN

0.00
  • Liminatus Pharma entered a definitive merger agreement dated May 17, 2026, to combine with InnocsAI, a biotech focused on CAR-T and antibody-based oncology therapies.
  • InnocsAI is set to merge into a newly formed Liminatus Delaware subsidiary, leaving the subsidiary as a wholly owned unit of Liminatus.
  • InnocsAI members are slated to receive 1,600,000,000 shares of Liminatus common stock priced at $0.2 per share, implying a transaction value of about $320 million.
  • The consideration also includes contingent value rights tied to 20% of future net proceeds from certain strategic transactions involving the acquired assets.
  • The deal is intended to expand Liminatus’ oncology pipeline, led by CAR-T programs including IBC101 for relapsed or refractory B-cell malignancies and INC101 for solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210804PRIMZONEFULLFEED9724410) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.